Board Appointments

Proteome Sciences PLC 23 July 2002 PROTEOME SCIENCES plc PRESS RELEASE 23rd July, 2002 PROTEOME SCIENCES ANNOUNCES TWO BOARD APPOINTMENTS: DR. WOLFGANG SCHULLER AS A NON-EXECUTIVE DIRECTOR AND JAMES GREEN AS COMMERCIAL DIRECTOR Proteome Sciences plc (Proteome Sciences), the AIM listed proteomics and modification of gene expression company, is pleased to announce that Dr. Wolfgang (Martin Herbert Helmut) Schuller, age 49, has today been appointed to the Board as a non-executive director and that Alfred James Green, age 54, has today been appointed to the Board as Commercial Director. Dr. Schuller is currently CEO of Aventis Research and Technologies GmbH & Co KG in Frankfurt. He began his career at Hoechst AG in 1985 and holds degrees in business administration and engineering. He has held a wide variety of finance and management positions in Germany and internationally. At the time of his appointment, Dr. Schuller commented : 'I am pleased to be invited on to the Board of Proteome Sciences as a non-executive director. By acquiring the proteomics division of Xzillion from Aventis Research and Technologies, Proteome Sciences has now been able to extend its critical mass to combine high out-put disease proteomics with high through-put processing. The acquisition gives Proteome Sciences a complete proteomic approach to address disease and significantly enhances its capacity to undertake strategic alliances with major biotechnology and pharmaceutical companies. Aventis R&T, which owns a 15.8% shareholding in Proteome Sciences, is committed to support the commercialisation of Proteome Sciences' outstanding proteomic capabilities in disease both internally for its own purposes and externally in life sciences for its applications in diagnostics, drug discovery and development.' Mr Green was a Director of Polymasc Pharmaceuticals plc until the 30th September 2001. Prior to this he held senior marketing and commercial development positions in a number of pharmaceutical and biotechnology companies over the past 30 years including, Beecham Pharmaceuticals, The Wellcome Foundation and Protherics plc. Commenting on his appointment, James Green said : 'I am delighted to have been elected to the Board of Proteome Sciences and will be focusing on the considerable commercial development opportunities for this exciting business and on securing significant licensing deals and further strategic partnerships with a range of pharmaceutical, biotechnology and diagnostic companies'. - ENDS - Enquiries and further information: Proteome Sciences plc Christopher Pearce, Chief Executive Tel: +44 (0)1932 865065 E-mail: christopher.pearce@proteome.co.uk Web: www.proteome.co.uk Public Relations Ikon Associates Adrian Shaw Tel: +44 (0)797 9900733 Paul Donkersley Tel: +44 (0)1483 535101 Mobile: +44(0)7967 646046 E-mail: paul@ikonassociates.com This information is provided by RNS The company news service from the London Stock Exchange